Multiple Sclerosis Drugs MarketPosted by ahila on April 26th, 2018 Multiple Sclerosis (MS) is a demyelinating disease that affects spinal cord and brain. Multiple sclerosis damages myelin sheath, material that surrounds and protects nerve cells. This damage blocks or slows down messages between brain and body. The exact cause of the Multiple Sclerosis disease is unknown but it is an autoimmune disease. Some of the major problems include doubled vision, psychological, mental disturbances and not having coordination in body movements. Most of the people diagnosed with MS are between the age 20 to 50 years and it can occur in young children and significantly older adults. The unmet need of drugs for the treatment of multiple sclerosis, extensive R&D pipelines and prevalence of the disease are driving factors for the market growth of Multiple Sclerosis drug market. According to the Atlas MS, there are about 2.3 million people are with multiple sclerosis, and most of the patients are not diagnosed with multiple sclerosis and certain parts of the world due to the lacking of healthcare infrastructure and unawareness. The advancements in the biomedical science about to create a profitable opportunities for multiple sclerosis drug makers in near future. However patent expiry of the key drugs is key restraint for multiple sclerosis market, In addition strengthening of regulatory requirements and procedures also making difficulties in steady market growth. A sample of this report is available upon request @ Multiple sclerosis drug market can be segmented into mode of administration, distribution channel, and drug class Based on route of administration, multiple sclerosis drugs market can be segmented into
Based on distribution channel, multiple sclerosis drugs market can be segmented into
Based on drug class, multiple sclerosis drugs market can be segmented into
To view TOC of this report is available upon request @ Like it? Share it! More by this author |